Proactive Investors - Run By Investors For Investors

Spectris shares rise after JP Morgan upgrades stock to 'overweight'

JP Morgan expects the company’s operating profit growth to accelerate over the next couple of years
Spectris is likely to have ended the year on a positive note, says JP Morgan

Spectris PLC's (LON:SXS) shares gained after JP Morgan Cazenove raised its rating on the stock to ‘overweight’ from ‘neutral’ and lifted its target price to 2,900p from 2,800p.

JP Morgan said it expects the company’s operating profit growth to accelerate over the next couple of years on the back of cost cuts, an organic revenue rise of at least 2.5% per year and a boost from acquisitions.

READ: Spectris buys Concept Life Sciences for £163mln

“We believe the lacklustre share price performance in 2017 was at least partly driven by sluggish organic growth early in 2017 and a lack of earnings growth relative to the sector,” it added.

“However, organic growth picked up in the second half and is likely to have ended the year on a positive note.”

The instrumentation and controls company is forecast to report flat operating profits in 2017 despite further revenue growth. The following year, however, JP Morgan estimates operating profits will gain at least 14% with organic revenue growth of at least 2.5%. It predicts operating profit growth of 12% in 2019.

Acquisitions to lift revenue

Spectris has completed five acquisitions over the past 18 months, including Millbrook and Concept Life Science, which deliver testing services to the auto and pharma industries, respectively.

JP Morgan expects the annual number of new model launches by the auto industry in Europe to rise by almost 50% between 2017 and 2020.

“We expect customers’ need to contain costs, a shortage of testing capacity and the need to reduce development times to result in increased use of testing services such as those of Millbrook,” it said.

“This should translate into double-digit growth in service-related revenue derived from the car industry.”

JP Morgan said the shares are trading at a discount to the sector and have a 16% upside potential to its revised price target of 2,900p.

Shares rose 2.9% to 2,558p in morning trading.

View full SXS profile View Profile

Spectris plc Timeline

September 02 2016

Related Articles

Dementia ward
January 15 2018
It's not exactly what the Silicon Valley companies would call a "pivot"; it's more of an acknowledgement that lighting solutions have to make full use of the available technology
Medical Scan
November 20 2017
The CE mark will enable Feedback to market not just to scientists, but radiologists everywhere, which should lead to a marked expansion in sales
ITM Power's first hydrogen station in London
July 11 2017
Electricity to hydrogen conversion technology has the potential to revolutionise the way we store renewable energy.

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use